Palbociclib is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
Fulvestrant in women with disease progression following endocrine therapy.
Dosage: Palbociclib capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant.
Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment.
Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability.
Side effect: Most common adverse reactions (incidence ≥10%) were neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and pyrexia.